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Introduction
Gap junctional intercellular communication (GJIC) allows the passage of small molecules of 1 kDa and is mediated by the presence of intercellular channels formed by connexins. 1 The loss or down-regulation of GJIC is a frequent event during neoplastic transformation 2 and conversely in tumor and transformed cells with low GJIC capacity the transfer of connexin genes leads to a significant reduction of the proliferation rate. 3 A point of interest is raised by the observation that in situ retroviral delivery of the Cx43 gene is able to restrain the growth of transformed cells originally characterized by their low GJIC capacity. 4 In gliomas, the limited expression of gap junctions has been reported in cells of rat and human origin. 5, 6 Although the molecular mechanisms underlying the antitumor role of Cx43 overexpression have not been elucidated, recent studies link the reversion of the transformed phenotype after Cx43 overexpression to a prolongation of G1 and S phases of the cell cycle and to a decreased expression of cell cycle regulatory genes, including cyclin A, D1, D2 and cyclin dependent kinases 5 and 6.
In vitro experiments have suggested that GJIC may also be one component of the so-called 'bystander effect', the phenomenon by which herpes simplex virus thymidine kinase (HSVtk)-transduced cells cause the death of nearby untransduced neoplastic cells when treated with ganciclovir (GCV). 8, 9 The in situ delivery into tumor cells of a drug sensitivity gene, such as HSVtk, and the subsequent pharmacological treatment with GCV is one of the approaches developed for gene therapy of cancer. 10 A rather wide range of pre-clinical experiences has been developed that confirmed some of the promising features of such a strategy. 11, 12 In patients with glioblastoma multiforme some prolongation of life expectancy has been obtained in spite of the low efficiency of tumor cell transduction (р0.2% of transduced cells, as assessed by fluorescence in situ hybridization of tumor biopsies). 12 This finding, as well as other in vitro and in vivo preclinical experiences, 10 suggests that the bystander effect plays a role in overcoming the limitations of gene transfer.
We previously confirmed that in vivo delivery of the HSVtk gene and GCV treatment restrain the growth of U-87 gliomas in nude mice and investigated some of the molecular features of the bystander effect in this model. 6 Our data suggested that the release of apoptotic vesicles caused by GCV-mediated death of glioma cells can cooperate with the presence of gap junctions to spread GCV-triphosphate to surrounding cells. The immune system can also have a role in the bystander effect, 13 and our recent data suggest that the combined transfer of interleukin 4 and HSVtk genes can have a stronger thera-peutic effect on experimental glioblastomas.
14 However, since the dual effect in vitro on tumor proliferation and on the bystander effect was also recently reported for a connexin, Cx26, 15 we were interested in verifying the consequences on the bystander effect of increased GJIC due to retrovirus-mediated in situ delivery of the Cx43 gene into glioblastoma cells.
Here we report experiments performed to verify the consequences on the bystander effect of increased GJIC due to retrovirus-mediated in situ delivery of the Cx43 gene into glioblastoma cells.
Results and discussion
We initially transfected U-87 cells with a eukaryotic expression plasmid containing the human Cx43 gene under the control of the cytomegalovirus promoter ( Figure 1a) . Four of the clones obtained after the transfection were examined and one, on Northern blot analysis, expressed Cx43 mRNA at high level (clone U-87.Cx2, Figure 1b ). In agreement with this, the evaluation of the GJIC capacity by dye-transfer assay, shown in Figure 1c , demonstrated that clone U-87.Cx2 has a higher average number of communicating cells than control U-87.wtr (wild-type G418 resistant) cells. The proliferation rate of clone U-87.Cx2 after 1 week in culture was found to be three times lower than in control cells (Figure 1d ). The in vivo growth rate of U-87.Cx2 tumors was also evaluated by subcutaneous inoculation in three groups of nude mice. U-87 tumors grew in all controls (n = 12), while U-87.Cx2 cells did not form tumors in the second group of mice (n = 10). A third group of mice (n = 17) were injected in one flank with U-87 cells and in the other with U-87 Cx 2 cells. U-87 tumors grew in 16 animals, while U-87.Cx2 tumors only grew in four and were considerably smaller than contralateral wild-type tumors. Overall wild-type U-87 tumors grew in 28/29 cases (96%) and U-87.Cx2 in 4/27 (15%). Thus, this set of experiments confirms the tumor suppressor effect of the Cx43 gene previously obtained in C6 rat glioma. 3 In order to prepare a retroviral producer cell line expressing human Cx43, we first cloned in the pLXSN plasmid the Cx43 coding sequence and transfected this construct by lipofection into the PA317 amphotropic packaging cell line. Twenty-three clones were analyzed after G418 selection and their transduction capacity checked on NIH-3T3 cells. The most efficient clone, PA317.Cx43.N3 (N3), had a titer of 1-4 × 10 4 c.f.u./ml. To confirm that retrovirus-mediated expression of Cx43 in glioma cells is functionally effective, we transduced U-87 cells with the N3 supernatant and characterized four of the derived clones by PCR on genomic DNA, RT-PCR and dye-transfer assay. PCR analysis on genomic DNA demonstrated the appropriate size of the integrated Cx43 gene and RT-PCR confirmed Cx43 expression. The dyetransfer assay demonstrated an increased level of GJIC capacity and the proliferation rate of transduced clones was slower than the control (data not shown). However, since the transduction efficiency of N3 cells was rather poor, we subsequently amplified the N3 titer by sequential transduction in psi-2 ecotropic and PA317 amphotropic cell lines. Several clones were isolated by G418 selection and one, clone N3.2.ii, was selected because of its titer (1.5 × 10 6 c.f.u./ml). The presence of a replicationcompetent virus in N3.2.ii cells was ruled out by investigating the rescue of G418 resistance in NIH3T3 cells and subsequent experiments were performed with N3.2.ii cells.
U-87 cells were transduced in vitro with the N3.2.ii supernatant and some of the derived clones characterized by competitive RT-PCR and by Western blotting (Figure 2 ). With these experiments we identified one clone, U-87.3, expressing high levels of Cx43 and one expressing low levels, clone U-87. 6 . The results of dyetransfer assay confirmed that clones 3 and 6 have, respectively, low and high communication capacity (Figure 3 ). We subsequently inoculated nude mice with U-87 wild-type, U-87.3 and U-87.6 cells. After a 3-month follow-up, 5/5 animals injected with clone U-87.3 (high level of expression) were tumor-free, while a tumor mass was present in mice grafted with U-87 wild-type and U-87.6 (low level of expression). Therefore, this series of experiments indicated that PA317.Cx43 retroviral producer cells are able to transfer a functional connexin gene into glioma cells in vitro and confirmed that the expression of this gene causes a regression of the proliferation rate of U-87 gliomas.
The capacity for inhibition of the neoplastic phenotype by in vivo transduction of the Cx43 gene was tested by co-injecting U-87 and N3.2.ii cells in nude mice. We found that the size of tumors was similar to controls for the entire follow-up of the experiment using a 1:1 ratio of U-87:N3.2.ii cells (Figure 4) . Similar results were obtained with C6 cells (data not shown). If the ratio of N3.2.ii:U-87 cells was increased five-fold, the size of subcutaneous gliomas was about 50% of controls for the first 3 weeks (P Ͻ 0.05, Figure 4 ), but the difference decreased subsequently.
To test whether Cx43 overexpression can strengthen the effect of HSVtk/GCV treatment, we subsequently coinjected six nude mice with U-87 cells, N3.2.ii cells and HSVtk retroviral producer cells (SBA cells; 1:1:1). Six other mice were injected with U-87, PA317 and SBA cells (1:1:1) as controls. Osmotic pumps set to release GCV for 2 weeks were implanted 5 days after tumor injection in both groups. After GCV treatment, no relevant difference could be demonstrated between animals injected or not by N3.2.ii cells (the average tumor sizes at day 20 were 0.67 ± 0.33 and 0.41 ± 0.25 mm 2 , respectively). Moreover, we performed a tumorigenicity assay by grafting N3.2.ii and PA317 wild-type cells in nude mice and in both cases we found that their growth is similar to that of U-87 cells alone.
GCV treatment was effective in limiting tumor growth of U-87 cells co-injected with SBA cells and could hide the effects of the contemporary transfer of the Cx43 gene. Therefore, we repeated these experiments with C6 tumors, since they are more aggressive and less responsive to the HSVtk/GCV system. 14 A control group of nude mice (n = 6) was injected subcutaneously with C6, PA317 and SBA cells (1:1:1) and another group (n = 7) with C6, N3.2ii and SBA cells (1:1:1). Also in this experimental setting, however, the presence of viral producer cells transducing the Cx43 gene did not modify the effects of GCV treatment. Average tumor size at 22 days was 40.2 mm 2 for the control group (C6, PA317 and SBA) and 41.3 mm 2 for mice injected with C6, N3.2.ii and SBA cells. Overall, the evidence provided by this work gives support to the putative therapeutic role of connexin overexpression in malignancies, based on the inhibition of the proliferation rate of neoplastic cells. Recent in vitro and in vivo evidences have demonstrated that the presence of gap junctions is a critical requirement for the bystander effect to take place. 9, 13, 16, 17 Our in vivo results, however, might have been limited by the insufficient transduction efficiency of the retrovirus vector that we have used, suggesting that Cx43/HSVtk bicistronic vectors or viral vectors of higher titer, such as adenovirus, are probably necessary to increase the bystander effect in vivo.
Materials and methods

Transfection of U-87 cells by a Cx43 eukaryotic expression plasmid
The open reading frame of human Cx43 was amplified by two rounds of PCR on genomic DNA. The first round 
Figure 4 Effects of the co-injection of U-87 human glioblastoma cells and viral producer cells transducing the Cx43 gene (N3.2.ii cells). On the left the in vivo growth rate in nude mice of U-87 tumors injected in a 1:1 ratio with Cx43 retroviral producer cells (N3.2.ii cells) is visible, on the right the growth of U-87 tumors injected i.a. a1:5 ratio with N3.2ii cells. Asterisks indicate that the difference is statistically significant (t test, P Ͻ 0.05).
was performed with primers Cx43L1-2 (TTCTTTCAGGT GGTGCCCAGG) and Cx43R1-2 (CTAGATCTCCA GGTCATCAGG), designed to exclude the amplification of a Cx43 pseudogene. 18 The initial denaturation at 94°C for 5 min was followed by 35 cycles at 94°C for 1 min, 62°C for 1 min and 72°C for 1.5 min. One microliter of the PCR mixture was subjected to a second round of amplification under similar conditions, using nested primers Cx43L1 (GGATCCAAGCTTATGGGTGACTGGAG CGC) and Cx43R1 (GGATCCAAGCTTCTAGATCTCCA GGTCAT), containing BamHI and HindIII restriction sites (underlined) at the 5′ end. The Cx43 DNA (1149 bp) was subsequently cloned into the HindIII site of the pRc/CMV plasmid (Invitrogen, Celbio, Italy) to yield pRc/CMV-Cx43.
The human U-87 glioma cell line, obtained from American Type Culture Collection (Rockville, MD, USA), was grown in Eagle's medium (EMEM) supplemented with 10% fetal calf serum, nonessential amino acids, sodium pyruvate, l-glutamine, streptomycin and penicillin. U-87 cells were lipofected by DOTAP (Boehringer Mannheim Italia, Milan, Italy) using 5 g of pRc/CMV-Cx43 or of pRc/CMV DNA purified by Qiagen (Celbio, Milan, Italy) tips 100. G418 selection was performed using 300 g/ml of active drug (Sigma Aldrich, Milan, Italy).
Characterization of Cx43 transfected/transduced clones DNA and total cellular RNA were extracted from cells using the IsoQuick nucleic acid extraction kit (ORCA Research, Bothell, USA) and RNAzol B (Biotech, Celbio, Italy), respectively. DNA samples for Southern blot (10 g) were digested with XbaI or HindIII, electrophoresed on a 0.8% agarose gel and blotted on to Hybond N+ membranes (Amersham, Milan, Italy). For Northern blot, 5-10 g of total RNA were electrophoretically separated on a 1.2% agarose/0.66 m formaldehyde gel and blotted overnight on to Hybond N+. Both Southern and Northern blots were prehybridized in 50% formamide, 5 × SSPE, 1 × Denhardt, 10% dextran sulphate and 1% SDS for 2 h at 42°C and then hybridized in the same buffer at 42°C overnight with a Cx43-ORF probe, radiolabeled with the Random Primed DNA Labeling Kit (Boehringer Mannheim), containing denatured salmon sperm DNA (100 g/ml). Probes were used with a specific activity of 10 9 c.p.m./g and a concentration of 1.5 × 10 6 c.p.m./ml. After hybridization, several 15-min washes were performed (one at room temperature with 2 × SSC, two at 65°C with 2 × SSC/0.1% SDS, one at 65°C with 0.5 × SSC/0.1% SDS and the last at 65°C with 0.5 × SSC) before exposure to Kodak (Milan, Italy) XAR films. RT-PCR was carried out using reagents of the cDNA Cycle Kit (Invitrogen), starting from 5 g of total RNA.
For competitive RT-PCR we synthesized the competitor primer Cx43-CRT with this sequence: CTTACCA TGCGACCAGTGGTGTTATTTCAATGGCTGCTCCTC. Nucleotides underlined correspond to the sequence of primer L4 and in Cx43 cDNA is separated by the remaining sequence by 40 nt. The amplification of Cx43 cDNA with primers L4/R1 (the sequence of R1 is above) will give a PCR product of 413 bp; the amplification with Cx43-CRT/R1 will give a product of 373 bp.
GJIC capacity of wild-type, transfected and transduced (see below) U-87 cells, was measured by dye-transfer assay, using lucifer yellow as previously described. 19 Cell proliferation was assayed by the Cell Proliferation Kit I, MTT (Boehringer Mannheim): 1-2 × 10 4 cells were plated in triplicate in 96-well microtest tissue culture plates (Costar, Milan, Italy) and the rate of MTT dehydrogenation was determined by using an ELISA reader at 540 nm. The proliferation rate was calculated as a percentage of increments on the value obtained at day 1 for each clone.
Western blotting was performed using anti-Cx43 antibodies (a gift from Dr E Riverdal, Institute for Cancer Research, Oslo, Norway) and the methods described in Ref. 19 .
Generation of retroviral producer cells expressing Cx43
To clone the Cx43-ORF in the retroviral vector pLXSN, 20 an aliquot of the PCR product obtained with primers Cx43L1-2 and Cx43R1-2 was re-amplified using primers Cx43L6 AAGCTTGTTAACATGGGTGACTGGAGCGC, containing at the 5′ end the underlined HindIII and HpaI restriction sites (not used for this cloning experiment), and Cx43R7 AAGCTTGGATCCCTAGATCTCCAGGT CAT, containing the HindIII and BamHI restriction sites (underlined), again using similar PCR conditions. The Cx43-ORF was first inserted into plasmid pCRII (TA Cloning System; Invitrogen) excised by BamHI digestion, and placed into the BamHI site of the pLXSN plasmid, yielding plasmid pLXSN-Cx43. PCR was used to identify clones carrying the Cx43-ORF in the correct orientation.
The retroviral producer cell line PA317.Cx43.N3 (N3), expressing the Cx43-ORF, was prepared by transfecting 70-80% confluent PA317 cells with 5 g of purified plasmid pLXSN-Cx43, using the transfection reagent DOTAP. After G418 selection (750 g/ml of active drug), the titer of resistant clones was tested on NIH 3T3 cells as described. 6 The absence of helper virus was demonstrated by serial infection assay on NIH3T3 cells. Two rounds of amplifications were subsequently performed by transduction of ecotropic psi-2 cells and amphotropic PA317 cells yielding to the isolation of the N3.2.ii producer clone (titer on NIH 3T3 cells 1.5 × 10 6 c.f.u./ml). The retroviral producer cell line PA317.STK.SBA (here defined as SBA), expressing the HSVtk gene, has a similar titer and has been described previously. 6 In control experiments a C6 clone transduced by SBA cells (clone C6.SBA.11) 14 was killed in 1 week by 50 m GCV added to the culture medium. In vivo the tumorigenicity of clone C6.SBA.11 was strongly reduced by GCV (30 mg/kg/per day) administration. 14 
In vivo experiments
In vivo experiments were performed on athymic 'nude' mice (females, 20- 
